{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:05:23Z","timestamp":1792101923675,"version":"4.4.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04119-x","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T04:49:31Z","timestamp":1745038171000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Association between time-varying serum lipid levels and all-cause mortality in haemodialysis and peritoneal dialysis patients"],"prefix":"10.1186","volume":"26","author":[{"given":"Zhenjian","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiongqiong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peifen","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,19]]},"reference":[{"key":"4119_CR1","doi-asserted-by":"crossref","unstructured":"Qishu L, Wei L. L-shaped association between dietary niacin intake and chronic kidney disease among adults in the USA: a cross-sectional study. Ren Fail. 2024;46(2).","DOI":"10.1080\/0886022X.2024.2399742"},{"issue":"4","key":"4119_CR2","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1001\/jamainternmed.2022.6817","volume":"183","author":"L Wang","year":"2023","unstructured":"Wang L, Xu X, Zhang M, Hu C, Zhang X, Li C, et al. Prevalence of chronic kidney disease in China: results from the sixth China chronic disease and risk factor surveillance. JAMA Intern Med. 2023;183(4):298\u2013310.","journal-title":"JAMA Intern Med"},{"key":"4119_CR3","doi-asserted-by":"crossref","unstructured":"Qunibi WY. Dyslipidemia in dialysis patients. Semin Dial. 2015 Jul-Aug;28(4):345\u2013\u200953.","DOI":"10.1111\/sdi.12375"},{"key":"4119_CR4","doi-asserted-by":"crossref","unstructured":"Tingting G, Wenqi X, Huanqing G, Jijuan Z, Jiaojiao Z, Kaiyue W, et al. Relationship between control of cardiovascular risk factors and chronic kidney disease progression, cardiovascular disease events, and mortality in Chinese adults. J Am Coll Cardiol. 2024;84(14).","DOI":"10.1016\/j.jacc.2024.06.041"},{"key":"4119_CR5","doi-asserted-by":"crossref","unstructured":"Natalia S. Dyslipidemia in peritoneal dialysis: implications for peritoneal membrane function and patient outcomes. biomedicines. 2024;12(10).","DOI":"10.3390\/biomedicines12102377"},{"key":"4119_CR6","doi-asserted-by":"crossref","unstructured":"Chieh-Li Y, Pei-Chun F, Cheng-Chia L, Jia-Jin C, Chao-Yu C, Yi-Ran T, et al. The role of maintaining lower LDL-C level during Statin treatment for advanced CKD patients. Atherosclerosis. 2024;399(0).","DOI":"10.1016\/j.atherosclerosis.2024.119042"},{"issue":"3","key":"4119_CR7","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1046\/j.1523-1755.2003.00803.x","volume":"63","author":"K Kalantar-Zadeh","year":"2003","unstructured":"Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003;63(3):793\u2013808.","journal-title":"Kidney Int"},{"key":"4119_CR8","doi-asserted-by":"crossref","unstructured":"Yeoungjee C, Janine B, Sonja S, Jutta P-D, Carmel MH, Goce D, et al. Longitudinal trend in lipid profile of incident peritoneal dialysis patients is not influenced by the use of biocompatible solutions. Perit Dial Int. 2015;36(2).","DOI":"10.3747\/pdi.2014.00291"},{"key":"4119_CR9","first-page":"0","volume":"13","author":"H Fanfan","year":"2012","unstructured":"Fanfan H, Jianping J, Jianghua C, Xueqing Y, Qiugen Z, Pingyan C, et al. China collaborative study on dialysis: a multi-centers cohort study on cardiovascular diseases in patients on maintenance dialysis. BMC Nephrol. 2012;13:0.","journal-title":"BMC Nephrol"},{"key":"4119_CR10","doi-asserted-by":"crossref","unstructured":"Yiping X, Zhong Z, Yi L, Zhijian L, Yi Z, Zhibin L, et al. Interaction effect between fasting plasma glucose and lipid profiles on mortality of peritoneal dialysis patients. Clin Kidney J. 2023;16(4).","DOI":"10.1093\/ckj\/sfac266"},{"key":"4119_CR11","doi-asserted-by":"crossref","unstructured":"Guiomar M, Stuart P, Virginia M, Andrea M, Ruth O, In\u00e9s G-L, et al. Determinants of progression and regression of subclinical atherosclerosis over 6 years. J Am Coll Cardiol. 2023;82(22).","DOI":"10.1016\/j.jacc.2023.09.814"},{"key":"4119_CR12","doi-asserted-by":"crossref","unstructured":"Simon C, Jessy Korina P-E, Katherine MS, Sushrut SW, Finnian RMC. Myeloperoxidase and the risk of CKD progression, cardiovascular disease, and death in the chronic renal insufficiency cohort (CRIC) study. Am J Kidney Dis. 2019;76(1).","DOI":"10.1053\/j.ajkd.2019.09.006"},{"key":"4119_CR13","doi-asserted-by":"crossref","unstructured":"Aleesha S, Mikhail K, James A, dL, Qi G, Katherine EM, Shushama A, et al. Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from getting to an improved understanding of low-density lipoprotein cholesterol and dyslipidemia management (GOULD). Clin Cardiol. 2022;45(12).","DOI":"10.1002\/clc.23923"},{"key":"4119_CR14","doi-asserted-by":"crossref","unstructured":"Jos\u00e9 T, Philippe Gabriel S, Deepak LB, Vera AB, Rafael D, Shaun GG, et al. Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the Odyssey outcomes randomized clinical trial. Eur Heart J. 2020;41(42).","DOI":"10.1093\/eurheartj\/ehaa498"},{"key":"4119_CR15","doi-asserted-by":"crossref","unstructured":"KDIGO. clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(0).","DOI":"10.1016\/j.kint.2023.09.002"},{"key":"4119_CR16","doi-asserted-by":"crossref","unstructured":"Jean-Philippe C, Holger T, Emanuele B, Olivier B, Johann B, Deepak LB, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020;42(14).","DOI":"10.1093\/eurheartj\/ehaa895"},{"key":"4119_CR17","doi-asserted-by":"crossref","unstructured":"Gloria Lena V, Jijia W, Scott MG. Chronic kidney disease and statin eligibility. J Clin Lipidol. 2020;15(1).","DOI":"10.1016\/j.jacl.2020.10.004"},{"key":"4119_CR18","unstructured":"Kevin F, Maria F-K, Svetlana S-M, Abigail L, Brian RB, Jessica ES, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet. 2013;383:9911."},{"key":"4119_CR19","doi-asserted-by":"crossref","unstructured":"Julia B, Kausik KR. Novel and future lipid-modulating therapies for the prevention of cardiovascular disease. Nat Rev Cardiol. 2023;20(9).","DOI":"10.1038\/s41569-023-00860-8"},{"key":"4119_CR20","doi-asserted-by":"crossref","unstructured":"Konrad Z, Wiktoria G, Jacek M, Jolanta M. Kidney and lipids: novel potential therapeutic targets for dyslipidemia in kidney disease? expert opin ther targets. 2022;26(11).","DOI":"10.1080\/14728222.2022.2161887"},{"key":"4119_CR21","doi-asserted-by":"crossref","unstructured":"David S, Danilo F, Thimoteus S. Proprotein convertase subtilisin\/kexin type 9 in kidney disease. Nephrol Dial Transpl. 2019;34(8).","DOI":"10.1093\/ndt\/gfz122"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04119-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04119-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04119-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T04:49:41Z","timestamp":1745038181000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04119-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,19]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4119"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04119-x","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,19]]},"assertion":[{"value":"1 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study followed the tenets of the Declaration of Helsinki, and informed consent was obtained from all the participants. The study was approved by the institutional review board of Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China (SYSKY-2024-860-01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"199"}}